doi: 10.1016/j.chom.2010.06.007 28 LangK.LangP.BauerC.DurantonC.WiederT.HuberS.et al
The evidence gap between supplement-class compounds and pharmaceutical-grade GLP-1 medications is substantial in both quantity and rigor
Fat-free mass changes during weight loss: methodological considerations and a critical look at GLP-1 receptor agonist trial data
Topics include the landscape of GLP-1 drug-device combination products in the US market, regulatory framing of acceptable UI differences, current CUHF study guidance and design fundamentals, case examples for pen injectors and autoinjectors, alternative CUHF approaches, device platform-based approaches for CA and HF data sharing, engineering considerations for generic GLP-1 injectors and drug-device interfaces, and CMC considerations for device evaluation
Side-Effect Tolerability and Who Should Consider Each Option Both medications cause gastrointestinal side effectsprimarily nausea, vomiting, constipation, and appetite suppression
Women treated with GLP-1 agonists for PCOS also demonstrated reductions in inflammatory markers such as C-reactive protein and improved lipid profiles
